About Evofem Biosciences
Evofem Biosciences is a publicly listed company based in San Diego (United States) founded in 2009, and was acquired by Aditx Therapeutics in December 2023. Therapeutics for womens reproductive care are developed. It operates on a Direct-to-Consumer (D2C) model. Evofem Biosciences has raised $100 million across 15 funding rounds from investors including Aditx Therapeutics, Woodford Investment Management and Adjuvant Capital. The company has 32 employees. Its chief executive, as recorded, is Saundra Pelletier. Evofem Biosciences offers products and services including Phexxi and Solosec. Its focus areas include Biotechnology and Women's Health. Its legal entity is Evofem Biosciences, Inc. Its competitors include Insmed, Affinivax and Aridis Pharma; 2 of its 3 listed competitors have raised funding.
Company details
Evofem Biosciences, Inc. is engaged in developing and commercializing innovative products for womens sexual and reproductive health. The company is recognized for its hormone-free contraceptive gel, Phexxi, which is FDA-approved and used on-demand by women. Operations are centered in the healthcare sector, specifically targeting unmet needs in contraception with localized, non-hormonal solutions. Products are designed to empower women by offering control and flexibility in reproductive choices. Market opportunities are pursued in the multi-billion dollar womens health industry, with ongoing efforts to expand internationally through partnerships.
- Headquarters San Diego, United States
- Employees 32
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website evofem.com
- Social LinkedIn X Facebook Instagram
- Acquired by Aditx Therapeutics (Dec 2023)
- Legal Name Evofem Biosciences, Inc.
- Annual Revenue$20.18 M (USD)4.23as on Dec 31, 2025
- Net Profit$391 K (USD)as on Dec 31, 2025
- EBITDA$2.06 M (USD)as on Dec 31, 2025
- Total Equity Funding$100M (USD)
in 15 rounds
- Latest Funding Round$925K (USD), Post-IPO
Jun 2025
- InvestorsAditx Therapeutics
& 4 more
- Employee Count32
- Acquired byAditx Therapeutics
(Dec 2023)
Products & Services of Evofem Biosciences
Evofem Biosciences offers a comprehensive portfolio of products and services, including Phexxi and Solosec.
Hormone-free contraceptive gel used on-demand by women.
Product focused on women's reproductive health solutions.
Funding Insights of Evofem Biosciences
Evofem Biosciences has successfully raised a total of $100M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $925 thousand completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100M
- Total Rounds 15
- Last Round Post-IPO — $925,000
- First Round $25M
(Dec 2009)
- Investors Count 4
Latest 10 of 15 funding rounds of Evofem Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $925,000 | Post-IPO | – | – | – |
| Apr 2025 | $750,000 | Post-IPO | – | – | – |
| Sep 2023 | $2.88M | Post-IPO | – | – | – |
| Mar 2023 | $1.38M | Post-IPO | – | – | – |
| Feb 2023 | $2.31M | Post-IPO | – | – | – |
| Oct 2020 | $25M | Post-IPO | – | – | |
| May 2020 | $15M | Post-IPO | – | – | – |
| Jun 2019 | $50M | Post-IPO | – | – | |
| Apr 2019 | $30M | Post-IPO | – | – | |
| Feb 2019 | $6.3M | Post-IPO | – | – | – |
5 investors in total: 5 institutional.
Investors in Evofem Biosciences
Evofem Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Aditx Therapeutics, Woodford Investment Management and Adjuvant Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is deployed for global health technology innovations. | adjuvantcapital.com | New York City, USA | ||
Biopharmaceutical company undergoing dissolution and asset distribution processes. | pdl.com | |||
Diversified asset management services are offered globally by Invesco. | invesco.com | Atlanta, United States | ||
Diversified investment portfolios are managed for clients by the firm. | 2014 | woodfordfunds.com | Swindon, United Kingdom | |
Immune monitoring solutions are provided to the medical community. | 2017 | aditxt.com | Loma Linda, United States |
Investor details for Evofem Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evofem Biosciences
36 people are tracked at Evofem Biosciences (12 in leadership, 4 in board & advisors, 20 in team); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Saundra Pelletier | CEO & President | Leadership |
Robin Belsaas | VP, Product Development | Leadership |
Mitch Rosen | National Director, Commercial Strategy & Innovation | Leadership |
Damian Frantz | Director, Strategic Markets, West | Leadership |
Ivy Zhang | CFO & Secretary | Leadership |
Amy Raskopf | Chief Business Development Officer | Leadership |
Ellen Thomas | Chief of Staff | Leadership |
David Birdsong | National Director, Sales | Leadership |
Kathy Gallo-Doyle | VP, Sales | Leadership |
Ram Gupta | Director, Strategic Markets, East | Leadership |
Katie Siegmund | Human Resources Director | Leadership |
David Friend | Chief Scientific Officer ► Innovating Healthcare Options For Women ♦ Amphora Contraceptive Gel | Leadership |
Tony O’Brien | Director | Board & advisors |
Kim Kamdar | Director | Board & advisors |
Lisa Rarick | Director | Board & advisors |
Colin Rutherford | Director | Board & advisors |
Richard Murawski | SVP, Operations | Team |
Ellen Harris | Senior Clinical Operations Manager | Team |
Jennifer R. | Regional Sales Representative | Team |
Benjamin W. | Regional Sales Representative | Team |
16 more people are available in the full profile.
Complete people profiles for Evofem Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Evofem Biosciences
Evofem Biosciences is a publicly listed company on the OTC with ticker symbol EVFM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Nov 2014
- Listed onNASDAQ: EVFM
- Listed entityEvofem Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS30048L3024
- Share price$0.01 (-6.67% on the day) · 2026-10-13
- Market capitalisation$927,711.00
- EPS (diluted, trailing year)$-0.11
- Volume (last session)34,284
Financials of Evofem Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $20.2M | $391,000 | $2.1M |
| 2024 | $19.4M | -$8.9M | -$5.4M |
| 2023 | $18.2M | $53.0M | -$16.1M |
| 2022 | $16.8M | -$76.7M | -$81.7M |
| 2021 | $8.2M | -$205.2M | -$164.4M |
Detailed financial statements for Evofem Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Evofem Biosciences
5 dated milestones of Evofem Biosciences across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Evofem Biosciences is founded.
- Funding First funding round of $25.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Aditx Therapeutics.
- Funding Latest funding round, Post-IPO, of $925K.
Competitors of Evofem Biosciences
Evofem Biosciences has 3 listed competitors in our database, 2 of them funded. They include Insmed, Affinivax and Aridis Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | 912 | Developer of small molecule inhibitors for rare lung diseases | ||
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| aridispharma.com | 2005 | San Jose, United States | $42.11M | 34 | Provider of human monoclonal antibodies against infectious diseases |
Detailed competitors of Evofem Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evofem Biosciences
The website of Evofem Biosciences (evofem.com) receives about 3.4K visits a month and ranks #6,956,947 among all websites worldwide, #6,837 in Biotechnology and Pharmaceuticals.
- Monthly visits3.4K
▲ 44.3% vs previous month
- Unique visitors1K
per month
- Global rank#6,956,947
among all websites
- Category rank#6,837
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.7
- Average visit44 sec
- DevicesDesktop 47% · Mobile 53%
Websites whose visitors overlap most with Evofem Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
associatesinwomenshealthcare.net | associatesinwomenshealthcare.net | 100% | #1,485,314 | – |
Top companies in Women's Health & Fertility
3 companies that operate in the same segment as Evofem Biosciences (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | ||
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | 861 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evofem Biosciences
Complete news archive for Evofem Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evofem Biosciences
Evofem Biosciences was founded in 2009.
Evofem Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Saundra Pelletier is the CEO of Evofem Biosciences, as recorded in our data.
Evofem Biosciences is a funded company, having raised a total of $100M across 15 funding rounds to date. The company's 1st funding round was a Post-IPO of $6.3M, raised on Dec 2009.
Evofem Biosciences has 32 employees.
Annual revenue of Evofem Biosciences is $20.18M as on Dec 31, 2025.
Evofem Biosciences, Inc. is engaged in developing and commercializing innovative products for womens sexual and reproductive health. The company is recognized for its hormone-free contraceptive gel, Phexxi, which is FDA-approved and used on-demand by women. Operations are centered in the healthcare sector, specifically targeting unmet needs in contraception with localized, non-hormonal solutions. Products are designed to empower women by offering control and flexibility in reproductive choices. Market opportunities are pursued in the multi-billion dollar womens health industry, with ongoing efforts to expand internationally through partnerships.
Evofem Biosciences's top competitors include Aridis Pharma, Insmed and Affinivax.
Evofem Biosciences offers Phexxi and Solosec.
Yes, Evofem Biosciences is publicly traded on OTC under the ticker symbol EVFM.
Evofem Biosciences has 5 investors. Key investors include Aditx Therapeutics, Woodford Investment Management, Adjuvant Capital, PDL BioPharma, and Invesco.
Evofem Biosciences operates through Evofem Biosciences, Inc..